|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-1-22
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Preclinical data demonstrate enhanced antitumor effect when lumiliximab, an anti-CD23 monoclonal antibody, is combined with fludarabine or rituximab. Clinical data from a phase 1 trial with lumiliximab demonstrated an acceptable toxicity profile in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). We therefore pursued a phase 1/2 dose-escalation study of lumiliximab added to fludarabine, cyclophosphamide, and rituximab (FCR) in previously treated CLL patients. Thirty-one patients received either 375 mg/m(2) (n = 3) or 500 mg/m(2) (n = 28) of lumiliximab in combination with FCR for 6 cycles. The toxicity profile was similar to that previously reported for FCR in treatment of relapsed CLL. The overall response rate was 65%, with 52% of patients achieving a complete response (CR), which compares favorably with the CR rate previously reported for the FCR regimen alone in relapsed CLL. The estimated median progression-free survival for all responders was 28.7 months. The addition of lumiliximab to FCR therapy is feasible, achieves a high CR rate, and does not appear to enhance toxicity in previously treated patients with CLL. A randomized trial comparing lumiliximab plus FCR with FCR alone is underway to define the benefit of this combination in relapsed CLL. This trial was registered at clinicaltrials.gov as NCT00103558.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-10477712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-11136261,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-11733578,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-11764079,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-11840283,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-12517774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-12592330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-15329427,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-15767647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-15767648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-16219797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-16344317,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-16353201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-16755224,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-17283363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-17283364,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-17658394,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-17671129,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-18032710,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-7888675,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19843887-8652811
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:ByrdJohn CJC,
pubmed-author:CastroJanuaroJ,
pubmed-author:FlinnIan WIW,
pubmed-author:HarrisSarahS,
pubmed-author:HeeremaNylaN,
pubmed-author:HughesSteveS,
pubmed-author:KippsThomas JTJ,
pubmed-author:LeighBryanB,
pubmed-author:LinThomas STS,
pubmed-author:MolinaArturoA,
pubmed-author:O'BrienSusanS,
pubmed-author:TangriShabnamS,
pubmed-author:WierdaWilliamW,
pubmed-author:WoodworthJamesJ,
pubmed-author:WynneDeeD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
21
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
489-95
|
|
pubmed:dateRevised |
2011-7-20
|
|
pubmed:meshHeading |
pubmed-meshheading:19843887-Aged,
pubmed-meshheading:19843887-Aged, 80 and over,
pubmed-meshheading:19843887-Antibodies, Monoclonal,
pubmed-meshheading:19843887-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19843887-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19843887-Cyclophosphamide,
pubmed-meshheading:19843887-Disease-Free Survival,
pubmed-meshheading:19843887-Dose-Response Relationship, Drug,
pubmed-meshheading:19843887-Drug Resistance, Neoplasm,
pubmed-meshheading:19843887-Female,
pubmed-meshheading:19843887-Humans,
pubmed-meshheading:19843887-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:19843887-Male,
pubmed-meshheading:19843887-Middle Aged,
pubmed-meshheading:19843887-Recurrence,
pubmed-meshheading:19843887-Vidarabine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
|
|
pubmed:affiliation |
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. john.byrd@osumc.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
